Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.

Elżbieta JabłonowskaPiotr PulikAnna KalinowskaJacek GąsiorowskiMiłosz ParczewskiMonika Bociąga-JasikŁukasz PulikEwa SiwakKamila Wójcik

Published in: Journal of medical virology (2017)

Dual therapy was effective and safe for the vast majority of antiretroviral-experienced subjects. Such therapy can be recommended especially for patients with renal impairment or NRTIs intolerance.

Keyphrases

hiv infected
antiretroviral therapy
hiv infected patients
end stage renal disease
newly diagnosed
human immunodeficiency virus
ejection fraction
chronic kidney disease
hiv aids
stem cells
hepatitis c virus
mesenchymal stem cells
patient reported
minimally invasive